Trending Now
- Kangana Ranaut had earlier approached the HC seeking that the FIR registered against her to be quashed.
- Ghana to fine airlines $3,500 for unvaccinated passengers
- Governor Arif Mohammed Khan junks Kerala CM Pinarayi Vijayan’s claims on VC postings
- PM calls for free & open Indo-Pacific
Businesswire
HeartSciences Showcases MyoVista® Wavelet ECG at 2018 China International Medicinal Equipment Fair (CMEF)
April 9, 2018
HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 China International Medicinal Equipment Fair (CMEF) Shanghai, China, April 11-14, 2018. CMEF has become the largest fair of medical devices, related products and services in the Asia-Pacific region. The fair widely covers 15,000 products, almost 4,200 medical device manufacturers from over 28 countries, and about 120,000 visitors and buyers who are government procurement agencies, hospital buyers and dealers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180409005020/en/
HeartSciences’ MyoVista wavECG Device with Informatics (Photo: Business Wire)
About HeartSciences
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wavECG device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG device is not currently FDA approved for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409005020/en/
MULTIMEDIA AVAILABLE :
https://www.businesswire.com/news/home/20180409005020/en/
Source: Businesswire